Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
J Endocrinol Invest ; 44(9): 1891-1896, 2021 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-33492600

RESUMO

PURPOSE: The diagnosis of vitamin D deficiency is based on the determination of total plasma 25-hydroxyvitamin D (25-OHD) concentrations, but the regulation of vitamin D 25-hydroxylation is not a major consideration and very little information is available on this activity. To check what factors could interfere with the activity of vitamin D-25-hydroxylase and thus alter the 25-OHD concentrations, we looked for potential correlations between 25-OHD and results of liver function tests in healthy adults. METHODS: This single-centre study was retrospective and consisted of evaluating the correlations between 25-OHD and the activities of aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), and bone alkaline phosphatase (BALP) in 349 healthy subjects aged from 18 to 65 years. In particular, in Group 1 (n = 119), we looked for correlations between 25OHD and all liver function tests and in Group 2 (n = 230) the correlation between 25OHD and BALP. RESULTS: In Group 1, we found no correlation between 25OHD and AST (r = - 0.03; p = 0.8), ALT (r = - 0.02; p = 0.91), GGT (r = - 0.08; p = 0.68), direct bilirubin (r = - 0.02; p = 0.89), indirect bilirubin (r = - 0.24; p = 0.21), and total bilirubin (r = - 0.24; p = 0.21) but one between 25OHD and ALP (r = - 0.2; p = 0.007); in Group 2, we found a significant negative correlation between 25-OHD and BALP (r = - 0.2; p = 0.0008). CONCLUSIONS: The correlations that we found suggest that ALP and BALP might be involved in the regulation of vitamin D-25-hydroxylase activity, but further studies are mandatory to confirm our assumptions.


Assuntos
Fosfatase Alcalina/metabolismo , Deficiência de Vitamina D/metabolismo , Vitamina D/metabolismo , Adolescente , Adulto , Idoso , Animais , Osso e Ossos/enzimologia , Humanos , Testes de Função Hepática , Masculino , Pessoa de Meia-Idade , Coelhos , Estudos Retrospectivos , Deficiência de Vitamina D/epidemiologia , Adulto Jovem
2.
Nutr Metab Cardiovasc Dis ; 20(3): 180-5, 2010 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19481430

RESUMO

BACKGROUND AND AIMS: Obesity is associated with an increased risk of developing atherosclerosis. Interleukin-20 (IL-20) is a pleiotropic cytokine thought to be involved in the onset and progression of atherosclerosis. The aim of this study was to determine whether circulating levels of IL-20 are elevated in obese women and whether they could be affected by a substantial decrease in body weight. METHODS AND RESULTS: Fifty obese and 50 age-matched, normal weight, premenopausal women participated in the study. Obese women entered into a medically supervised weight loss program aimed at reducing body weight to 90% of baseline. We measured anthropometric, glucose and lipid parameters, and IL-20, C-Reactive Protein (CRP) and interleukin-10 (IL-10) circulating levels. Circulating IL-20 and CRP levels were significantly higher in obese than control women (P=0.01), while IL-10 levels were significantly lower; IL-20 levels were positively associated with body weight (r=0.35; P=0.02) and visceral fat (waist-hip ratio; r=0.32; P=0.025). Caloric restriction-induced weight loss (>10% of original weight) over 6 months reduced IL-20 levels from 152 (112/184) to 134 (125/153)pg/ml (median and 25%/75%; P=0.03), and it was positively associated with changes in body mass index and waist-hip ratio. CONCLUSION: In premenopausal obese women, IL-20 levels are higher than matched normal weight control women, are associated with body weight and waist-hip ratio, and are reduced by weight loss.


Assuntos
Interleucinas/sangue , Obesidade/sangue , Redução de Peso/fisiologia , Adulto , Glicemia/análise , Índice de Massa Corporal , Proteína C-Reativa/análise , Jejum , Feminino , Humanos , Insulina/sangue , Interleucina-10/sangue , Pessoa de Meia-Idade , Pré-Menopausa , Triglicerídeos/sangue , Relação Cintura-Quadril
3.
Andrologia ; 41(6): 361-8, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19891634

RESUMO

Reproductive dysfunction is a consequence of diabetes, but the underlying mechanisms are poorly understood. This study investigated the histological and molecular alterations in the testes of rats injected with streptozotocin at prepuperal (SPI rats) and adult age (SAI rats) to understand whether diabetes affects testicular tissue with different severity depending on the age in which this pathological condition starts. The testes of diabetic animals showed frequent abnormal histology, and seminiferous epithelium cytoarchitecture appeared altered as well as the occludin distribution pattern. The early occurrence of diabetes increased the percentage of animals with high number of damaged tubules. The interstitial compartment of the testes was clearly hypertrophic in several portions of the organs both in SPI and SAI rats. Interestingly, fully developed Leydig cells were present in all the treated animals although abnormally distributed. Besides the above-described damages, we found a similar decrease in plasma testosterone levels both in SPI and SAI rats. Oxidative stress (OS) is involved in the pathogenesis of various diabetic complications, and in our experimental models we found that manganese superoxide dismutase was reduced in diabetic animals. We conclude that in STZ-induced diabetes, the altered spermatogenesis, more severe in SPI animals, is possibly due to the effect of OS on Leydig cell function which could cause the testosterone decrease responsible for the alterations found in the seminiferous epithelium of diabetic animals.


Assuntos
Diabetes Mellitus Experimental/patologia , Diabetes Mellitus Experimental/fisiopatologia , Testículo/patologia , Testículo/fisiopatologia , Envelhecimento , Animais , Barreira Hematotesticular , Hipertrofia , Células Intersticiais do Testículo/patologia , Masculino , Proteínas de Membrana/metabolismo , Ocludina , Estresse Oxidativo , Ratos , Epitélio Seminífero/patologia , Túbulos Seminíferos/metabolismo , Túbulos Seminíferos/patologia , Espermatogênese , Superóxido Dismutase/metabolismo , Testosterona/sangue , Distribuição Tecidual
4.
Int J Impot Res ; 19(5): 486-91, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17673936

RESUMO

In the present study, we tested the effect of a Mediterranean-style diet on sexual function in women with the metabolic syndrome. Women were identified in our database of subjects participating in controlled trials evaluating the effect of lifestyle changes and were included if they had a diagnosis of female sexual dysfunction (FSD) associated with a diagnosis of metabolic syndrome, a complete follow-up in the study trial and an intervention focused mainly on dietary changes. Fifty-nine women met the inclusion/exclusion criteria; 31 out of them were assigned to the Mediterranean-style diet and 28 to the control diet. After 2 years, women on the Mediterranean diet consumed more fruits, vegetables, nuts, whole grain and olive oil as compared with the women on the control diet. Female sexual function index (FSFI) improved in the intervention group, from a mean basal value of 19.7+/-3.1 to a mean post-treatment value of 26.1+/-4.1 (P=0.01), and remained stable in the control group. C-reactive protein (CRP) levels were significantly reduced in the intervention group (P<0.02). No single sexual domain (desire, arousal, lubrication, orgasm, satisfaction, pain) was significantly ameliorated by the dietary treatment, suggesting that the whole female sexuality may find benefit from lifestyle changes. A Mediterranean-style diet might be effective in ameliorating sexual function in women with metabolic syndrome.


Assuntos
Dieta Mediterrânea , Síndrome Metabólica/dietoterapia , Disfunções Sexuais Fisiológicas/dietoterapia , Disfunções Sexuais Psicogênicas/dietoterapia , Adulto , Feminino , Humanos , Síndrome Metabólica/complicações , Pessoa de Meia-Idade , Comportamento Sexual/fisiologia , Comportamento Sexual/psicologia , Disfunções Sexuais Fisiológicas/complicações , Disfunções Sexuais Psicogênicas/complicações
5.
Lung Cancer ; 33(2-3): 163-9, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11551411

RESUMO

As reported earlier, p53 antibodies are detected in the sera of patients with different types of cancer, including lung cancer. In contrast, in the serum of healthy subjects the presence of anti-p53 antibodies is extremely rare. We collected the venous blood samples of 109 patients affected with lung cancer (LC): 57 patients (46 M, 11 F) with non-small-cell carcinoma (NSCLC), 52 others (40 M, 12 F) with small-cell carcinoma (SCLC). Serum p53 antibodies were assayed using ELISA method and all positive sera were confirmed by Western-blot method. In addition, using IRMA methods we assayed serum CEA, TPA, CYFRA21-1 and NSE. Serum p53Ab are detectable (p53Ab-positive) in 35/109 (32.1%) patients with lung cancer. About 17/57 (29.8%) patients affected with NSCLC and 18/52 (34.6%) with SCLC were p53Ab-positive. CEA, TPA, CYFRA21-1 and NSE sensitivity in LC patients (NSCLC+SCLC) is 50.5%, 58.7%, 42.2%, 35.8%, respectively. The lower sensitivity (32.1%) of serum p53Ab is connected with the higher specificity and diagnostic accuracy (100% and 69%, respectively). Out of 35 patients p53Ab-positive, five (14.3%) exhibit only serum p53Ab, while serum values of the established tumor markers were lower than cut-off. Serum p53Ab assessment is a simple and a low-cost assay with a good specificity and diagnostic accuracy that in LC patients can be used at least in association with established tumor markers.


Assuntos
Anticorpos Antineoplásicos/sangue , Antígenos de Neoplasias/imunologia , Biomarcadores Tumorais/sangue , Carcinoma Pulmonar de Células não Pequenas/imunologia , Carcinoma de Células Pequenas/imunologia , Neoplasias Pulmonares/imunologia , Proteína Supressora de Tumor p53/imunologia , Idoso , Idoso de 80 Anos ou mais , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Masculino , Estadiamento de Neoplasias , Sensibilidade e Especificidade
6.
J Pediatr Endocrinol Metab ; 14(9): 1635-9, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11795654

RESUMO

OBJECTIVE: It is rare that manufacturers report age-related FT3, FT4 and TSH normal ranges in healthy children. STUDY DESIGN: Using a solid phase time-resolved fluoroimmunometric method, we determined serum FT3, FT4 and TSH in 3,360 healthy children, age 2-16 years, that we grouped into two age ranges (2-7 yr and 9-16 yr). RESULTS: Boys' and girls' mean serum thyroid hormone values substantially overlap in all age groups. In the age range 2-7 yr, FT3, FT4 and TSH values were 0.10-0.67 ng/dl (mean 0.37 ng/dl), range 0.45-2.29 ng/dl (mean 1.18 ng/dl) and 0.10-5.9 microU/ml (mean 2.2 microU/ml), respectively. In the age range 9-16 yr, FT3, FT4 and TSH values were 0.11-0.53 ng/dl (mean 0.35 ng/dl), 0.69-1.69 ng/dl (mean 1.07 ng/dl) and 0.20-6.1 microU/ml (mean 2.3 pU/ml), respectively. CONCLUSION: Our results represent a useful set of reference values in children and can help physicians in the management of thyroid diseases.


Assuntos
Tireotropina/sangue , Tiroxina/sangue , Tri-Iodotironina/sangue , Adolescente , Envelhecimento/sangue , Criança , Pré-Escolar , Feminino , Humanos , Masculino , Concentração Osmolar , Valores de Referência
7.
Tumori ; 85(1): 32-4, 1999.
Artigo em Inglês | MEDLINE | ID: mdl-10228494

RESUMO

AIMS AND BACKGROUND: E-cadherin, also known as uvomorulin or cell-CAM 120/80, is one of the subclasses of cadherins, CA(2+)-dependent cell adhesion molecules. Several recent studies have suggested that loss of E-cadherin may be associated with tumor progression, such as in lung, gastric, hepatocellular, breast and prostatic carcinoma. Assessment of E-cadherin serum levels in lung cancer showed a relation to histologic type. METHODS AND STUDY DESIGN: Using an enzyme immunoassay, we determined E-cadherin serum levels in 79 patients affected with lung cancer (stage I-IV), 9 patients with breast cancer, 23 patients with different benign diseases, and 20 healthy patients. RESULTS: At a specificity level of 90%, E-cadherin diagnostic sensitivity was 66.6%, 47.6% and 43.7% in patients affected with squamous cell carcinoma, small cell carcinoma and adenocarcinoma, respectively. CONCLUSIONS: Preliminary results suggest the use of serum E-cadherin as a prospective tumor marker.


Assuntos
Caderinas/sangue , Carcinoma Pulmonar de Células não Pequenas/sangue , Carcinoma de Células Pequenas/sangue , Neoplasias Pulmonares/sangue , Neoplasias Pulmonares/patologia , Carcinoma Pulmonar de Células não Pequenas/patologia , Carcinoma de Células Pequenas/patologia , Feminino , Humanos , Masculino , Estadiamento de Neoplasias , Sensibilidade e Especificidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA